Bluebird Bio | BLUE - Заемный капитал



Заемный капитал Изменить Дата
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
Amgen USD 51.86B 27M 2026-06
Arrowhead Research USD 824.07M 401.34M 2026-06
Biogen USD 7.29B 1B 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Gilead Sciences USD 23.83B 2.97B 2026-06
Incyte USD 28.42M 994K 2026-06
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
Moderna USD 597M 6M 2026-06
Nektar Therapeutics USD 60.27M 2.89M 2026-03
Novartis USD 37.49B 42M 2026-06
Pfizer USD 60.5B 70M 2026-06
PTC Therapeutics USD 535.52M 248.58M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Sangamo BioSciences USD 0 0 2022-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Tectonic Therapeutic USD 17K 26K 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12